drug · antibody
HUMIRA
updated 6mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval472 co-mentions · 155 sources
- drugadalimumab359 co-mentions · 156 sources
- drugAMJEVITA188 co-mentions · 94 sources
- drugABRILADA176 co-mentions · 88 sources
- drugYUSIMRY172 co-mentions · 86 sources
- company$ABBVAbbVie Inc.122 co-mentions · 61 sources
- drugCYLTEZO48 co-mentions · 12 sources
- drugIDACIO32 co-mentions · 8 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.
targets
Tumor necrosis factor
all catalysts(0)
nothing on the calendar yet
Trials studying HUMIRA
- phase1A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
- phase4A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
- phase3A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- phase3Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- phase1A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
- phase4A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
- phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- phase3A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
News(10)
- Deaths, failed trials and other recent setbacks in the autoimmune spaceNovartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…biospace · 1d ago
- AbbVie pens $1.4B deal for deprioritized IBD drug from NxeraAbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.fiercebiotech · 13d ago
- AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on dealsStrong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.biospace · 17d ago
- 5 new drug launches that defied industry expectationsA clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.biospace · 20d ago
- AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectationsAbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising q…biospace · 25d ago
- Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye diseaseBrepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infect…biospace · 26d ago
- Celltrion picks up another Kaigene autoimmune antibody for up to $580.5MCelltrion has licensed a preclinical antibody targeting autoimmune conditions from Maryland-based biotech Kaigene in a deal worth up to $580.5 million, marking another step in the South Korean drug…fiercebiotech · 26d ago
- Roivant, continuing ascent, claims another victory for rare disease drugShortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one an…biopharma_dive · 26d ago
- STAT+: Roivant says closely watched immune drug succeeded in new eye diseaseAn immune drug from Roivant could be headed to a new market, after the company reported positive trials in the eye disease non-infectious uveitis.stat · 27d ago
- As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune visionAbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster ca…biospace · 28d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that